AstraZeneca's Dobber On Ramping In Renal, Expanding In CV And Business Development

Biopharmaceuticals President Ruud Dobber talked to Scrip about the launches of Lokelma and roxadustat in kidney disease, building with a high bar in cardiovascular disease and expanding in cell and gene therapy.

Ruud Dobber
AstraZeneca's Dobber talked to Scrip at J.P. Morgan • Source: AstraZeneca

This year AstraZeneca PLC Biopharmaceuticals President Ruud Dobber is focused on executing on the company's expansion into kidney disease with the launch of Lokelma (sodium zirconium cyclosilicate) underway for hyperkalemia and a second potential approval, roxadustat, anticipated later in 2020.

Dobber, who oversees AstraZeneca's global drug portfolio outside of oncology, talked with Scrip at the J.P. Morgan Healthcare conference in...

More from Strategy

More from Business

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.